Oren Livnat
Stock Analyst at HC Wainwright & Co.
(4.56)
# 246
Out of 4,970 analysts
140
Total ratings
54.48%
Success rate
21.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $26.45 | +145.75% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $5.11 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $38.37 | +30.31% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $7.01 | +78.32% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $95.35 | -1.42% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $8.95 | +123.46% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $129.50 | +67.57% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $7.85 | +1.91% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $15.76 | +33.25% | 16 | Mar 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $57.63 | +26.67% | 9 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.20 | +275.00% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $5.54 | +35.38% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.88 | +813.14% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $2.90 | +1,951.72% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.30 | +66,076.47% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $26.45
Upside: +145.75%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.11
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $38.37
Upside: +30.31%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $7.01
Upside: +78.32%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $95.35
Upside: -1.42%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $8.95
Upside: +123.46%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $129.50
Upside: +67.57%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $7.85
Upside: +1.91%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $15.76
Upside: +33.25%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $57.63
Upside: +26.67%
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.20
Upside: +275.00%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $5.54
Upside: +35.38%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.88
Upside: +813.14%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $2.90
Upside: +1,951.72%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.30
Upside: +66,076.47%